Table 1 Baseline characteristics according to treatment assignment
Characteristics | Total (n = 148) | AMCPR (n = 74) | Placebo (n = 74) |
|---|---|---|---|
Patients characteristics | |||
Age, year | 77.0 (68.3–83.0) | 77.5 (70.0–83.0) | 77.0 (67.0–83.0) |
Sex | |||
Male | 100 (67.6) | 47 (63.5) | 53 (71.6) |
Female | 48 (32.4) | 27 (36.5) | 21 (28.4) |
Comorbidities | |||
Coronary artery syndrome | 22 (14.9) | 10 (13.5) | 12 (16.2) |
Atrial fibrillation | 7 (4.7) | 3 (4.1) | 4 (5.4) |
Chronic heart failure | 5 (3.4) | 2 (2.7) | 3 (4.1) |
Stroke | 9 (6.1) | 4 (5.4) | 5 (6.8) |
Hypertension | 64 (43.2) | 31 (41.9) | 33 (44.6) |
Diabetes | 49 (33.1) | 25 (33.8) | 24 (32.4) |
Pulmonary disease | 14 (9.5) | 3 (4.1) | 11 (14.9) |
Neurologic disease | 18 (12.2) | 10 (13.5) | 8 (10.8) |
Kidney disease | 11 (7.4) | 6 (8.1) | 5 (6.8) |
Liver disease | 2 (1.4) | 1 (1.4) | 1 (1.4) |
Cancer | 21 (14.2) | 9 (12.2) | 12 (16.2) |
Cardiac arrest characteristics | |||
Witnessed | 92 (62.2) | 47 (63.5) | 45 (60.8) |
Bystander chest compression | 91 (61.5) | 46 (62.2) | 45 (60.8) |
Prehospital AED | 13 (8.8) | 9 (12.2) | 4 (5.4) |
Initial rhythm | |||
Asystole | 106 (71.6) | 50 (67.6) | 56 (75.7) |
Pulseless electrical activity | 32 (21.6) | 17 (23.0) | 15 (20.3) |
Ventricular fibrillation a | 9 (6.1) | 6 (8.1) | 3 (4.1) |
Presumed arrest cause | |||
Cardiac | 77 (52.7) | 37 (50.7) | 40 (54.8) |
Other medical | 64 (43.8) | 34 (46.6) | 30 (41.1) |
Prehospital low flow time, min | 28.0 (23.0–34.0) | 29.0 (25.0–33.3) | 26.0 (21.0–34.0) |
Time from ED arrival to | |||
Epinephrine administration, min | 1.0 (1.0–2.0) | 1.0 (1.0–3.0) | 1.0 (0.0–2.0) |
Vasopressin or normal saline administration, min | 4.0 (3.0–6.0) | 5.0 (3.0–5.0) | 4.0 (3.0–6.0) |
Treatment after ROSC | |||
PCI | 9 (6.1) | 5 (6.8) | 4 (5.4) |
TTM | 34 (23.0) | 16 (21.6) | 18 (24.3) |
RRT | 9 (6.1) | 4 (5.4) | 5 (6.8) |